The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation

Seminars in Hematology

Volumn 43, Issue SUPPL. 2, 2006, Pages

  Foss, Francine M ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; BUSULFAN; CARMUSTINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PURINE DERIVATIVE; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHEMOTHERAPY; CHIMERA; CLINICAL TRIAL; DENDRITIC CELL; DONOR SELECTION; EFFECTOR CELL; FOLLICULAR LYMPHOMA; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; GRAFT VERSUS LYMPHOMA EFFECT; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; IRRADIATION; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER TOXICITY; LUNG DISEASE; LYMPHOPROLIFERATIVE DISEASE; MORBIDITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PUVA; REMISSION; REVIEW; STEM CELL; T CELL DEPLETION; VEIN OCCLUSION; VIRUS REACTIVATION; WHOLE BODY RADIATION;

EID: 33645009047     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2005.12.007     Document Type: Article

References (62)

1. A. Gratwohl, H. Baldomero, J. Passweg, A. Urbano-Ispizua Increasing use of reduced intensity conditioning transplants Report of the 2001 EBMT activity survey Bone Marrow Transplant 30 2002 813 831
2. H.M. Lazarus, R.P. Gale Blood cell and bone marrow transplants Bone Marrow Transplant 18 1996 839 841
3. S. Giralt, I. Khouri, R. Champlin Non myeloablative "mini transplants" Cancer Treat Res 101 1999 97 108
4. R. Champlin, I. Khouri, A. Shimoni, J. Gajewski, S. Kornblau, J. Molldrem Harnessing graft-versus-malignancy Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy Br J Haematol 111 2000 18 29
5. R. Wong, S.A. Giralt, T. Martin, D.R. Couriel, A. Anagnostopoulos, C. Hosing Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years Blood 102 2003 3052 3059
6. M.L. Sorror, M.B. Maris, B. Storer, B.M. Sandmaier, R. Diaconescu, C. Flowers Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning Influence of pretransplantation comorbidities Blood 104 2004 961 968
7. S. Slavin, A. Nagler, E. Naparstek, Y. Kapelushnik, M. Aker, G. Cividalli Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 1998 756 763
8. M. de Lima, A. Anagnostopoulos, M. Munsell, M. Shahjahan, N. Ueno, C. Ippoliti Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 104 2004 865 872
9. P. Anderlini, R. Saliba, S. Acholonu, G.J. Okoroji, M. Donato, S. Giralt Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease Low transplant-related mortality and impact of intensity of conditioning regimen Bone Marrow Transplant 35 2005 943 951
10. M.R. Pelot, D.A. Pearson, K. Swenson, G. Zhao, J. Sachs, Y.G. Yang Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen Biol Blood Marrow Transplant 5 1999 133 143
11. R. Storb, R.F. Raff, F.R. Appelbaum, H.J. Deeg, T.C. Graham, F.G. Schuening Fractionated versus single-dose total body irradiation at low and high dose rates to condition canine littermates for DLA-identical marrow grafts Blood 83 1994 3384 3389
12. H.J. Deeg, C. Anasetti, E. Petersdorf, R. Storb, K. Doney, J.A. Hansen Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors Blood 83 1994 3417 3418
13. R. Storb, C. Yu, J.L. Wagner, H.J. Deeg, R.A. Nash, H.P. Kiem Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation Blood 89 1997 3048 3054
14. J.L. Wagner, R. Storb Preclinical large animal models for hematopoietic stem cell transplantation Curr Opin Hematol 3 1996 410 415
15. C. Yu, K. Seidel, R.A. Nash, H.J. Deeg, B.M. Sandmaier, A. Barsoukov Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts Blood 91 1998 2581 2587
16. R. Storb, C. Yu, T. Barnett, J.L. Wagner, H.J. Deeg, R.A. Nash Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation Blood 94 1999 1131 1136
17. R. Storb, C. Yu, B. Sandmaier, P. McSweeney, G. Georges, R. Nash Mixed hematopoietic chimerism after hematopoietic stem cell allografts Transplant Proc 31 1999 677 678
18. I.F. Khouri, M. Keating, M. Korbling, D. Przepiorka, P. Anderlini, S. O'Brien Transplant-lite Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol 16 1998 2817 2824
19. M. Weisser, M. Schleuning, G. Ledderose, B. Rolf, S. Schnittger, C. Schoch Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease Bone Marrow Transplant 34 2004 1083 1088
20. S. Giralt, E. Estey, M. Albitar, K. van Besien, G. Rondon, P. Anderlini Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy Harnessing graft-versus-leukemia without myeloablative therapy Blood 89 1997 4531 4536
21. S. Giralt, P.F. Thall, I. Khouri, X. Wang, I. Braunschweig, C. Ippolitti Melphalan and purine analog-containing preparative regimens reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 97 2001 631 637
22. D.S. Ritchie, J. Morton, J. Szer, A.W. Roberts, S. Durrant, P. Shuttleworth Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan Biol Blood Marrow Transplant 9 2003 435 442
23. C. Grosskreutz, V. Ross, E. Scigliano, S. Fruchtman, L. Isola Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation Biol Blood Marrow Transplant 9 2003 453 459
24. R. Childs, E. Clave, N. Contentin, D. Jayasekera, N. Hensel, S. Leitman Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation Full donor T-cell chimerism precedes alloimmune responses Blood 94 1999 3234 3241
25. R. Childs, J. Barrett Nonmyeloablative stem cell transplantation for solid tumors Expanding the application of allogeneic immunotherapy Semin Hematol 39 2002 63 71
26. D. Niederwieser, M. Maris, J.A. Shizuru, E. Petersdorf, U. Hegenbart, B.M. Sandmaier Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases Blood 101 2003 1620 1629
27. M. Sykes, F. Preffer, S. McAfee, S.L. Saidman, D. Weymouth, D.M. Andrews Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation Lancet 353 1999 1755 1759
28. B.R. Dey, S. McAfee, R. Sackstein, C. Colby, S. Saidman, D. Weymouth Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation Biol Blood Marrow Transplant 7 2001 604 612
29. P.D. Kottaridis, D.W. Milligan, R. Chopra, R.K. Chakraverty, S. Chakrabarti, S. Robinson In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 96 2000 2419 2425
30. S. Chakrabarti, S. Mackinnon, R. Chopra, P.D. Kottaridis, K. Peggs, P. O'Gorman High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation Potential role of Campath-1H in delaying immune reconstitution Blood 99 2002 4357 4363
31. A.Y. Ho, S. Devereux, G.J. Mufti, A. Pagliuca Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions Bone Marrow Transplant 31 2003 551 557
32. R.D. Faulkner, C. Craddock, J.L. Byrne, P. Mahendra, A.P. Haynes, H.G. Prentice BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases GVHD, toxicity, and survival in 65 patients Blood 103 2004 428 434
33. A.Y. Ho, A. Pagliuca, M. Kenyon, J.E. Parker, A. Mijovic, S. Devereux Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning Blood 104 2004 1616 1623
34. P. McLaughlin Biotherapy for lymphoma Curr Oncol Rep 2 2000 157 162
35. P.P. Major, R.P. Agarwal, D.W. Kufe Clinical pharmacology of deoxycoformycin Blood 58 1981 91 96
36. B.S. Mitchell, Y. Sidi, M. Hershfield, C.A. Koller Biochemical consequences of adenosine deaminase inhibition in vivo. Differential effects in acute and chronic T cell leukemia Ann N Y Acad Sci 451 1985 129 137
37. D.A. Carson, J. Kaye, J.E. Seegmiller Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine J Immunol 121 1978 1726 1731
38. + T cells in peripheral blood of deoxycoformycin-treated patients J Natl Cancer Inst 83 1991 1678 1679
39. M.R. Grever, M.F. Siaw, W.F. Jacob, J.A. Neidhart, J.S. Miser, M.S. Coleman The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy Blood 57 1981 406 417
40. F.M. Foss Combination therapy with purine nucleoside analogs Oncology (Williston Park) 14 2000 31 35
41. F.M. Foss Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma Single-agent and combination studies Semin Oncol 27 2000 58 63
42. K.B. Miller, T.F. Roberts, G. Chan, D.P. Schenkein, D. Lawrence, K. Sprague A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease Bone Marrow Transplant 33 2004 881 889
43. K.B. Miller, D.P. Schenkein, R. Comenzo, J.K. Erban, T. Fogaren, C.A. Hirsch Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation Ann Hematol 68 1994 15 20
44. G.W. Chan, G. Gorgun, K.B. Miller, F.M. Foss Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease Biol Blood Marrow Transplant 9 2003 170 176
45. S.Z. Pavletic, R.G. Bociek, J.M. Foran, R.J. Rubocki, C.A. Kuszynski, J.L. Wisecarver Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation Transplantation 76 2003 877 881
46. B. Sandmaier, D. Maloney, M. Maris, T. Chauncey, M. Pulsipher, W. Bethge Conversion of low donor chimerism following nonmyeloablative conditioning for hematopoietic cell transplantation (HCT) using pentostatin and donor lymphocyted infusion (DLI) Blood 103 2004 186 (abstr)
47. G. Hale, S. Cobbold, H. Waldmann T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation Transplantation 45 1988 753 759
48. P.J. Martin, J.A. Hansen, C.D. Buckner, J.E. Sanders, H.J. Deeg, P. Stewart Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts Blood 66 1985 664 672
49. P.J. Martin, J.A. Hansen, R. Storb, E.D. Thomas T cell depletion of donor marrow for prevention of acute graft-versus-host disease Haematol Blood Transfus 29 1985 42 43
50. M. Starobinski, E. Roosnek, G. Hale, E. Roux, C. Helg, B. Chapuis T cell depletion of allogeneic peripheral blood stem cells Bone Marrow Transplant 21 1998 429 430
51. V.T. Ho, R.J. Soiffer The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation Blood 98 2001 3192 3204
52. R.E. Champlin, J.R. Passweg, M.J. Zhang, P.A. Rowlings, C.J. Pelz, K.A. Atkinson T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings Advantage of T-cell antibodies with narrow specificities Blood 95 2000 3996 4003
53. R. Breuer, R. Or, G. Lijovetzky, E. Naparstek, D. Engelhard, J. Lafair Interstitial pneumonitis in T cell-depleted bone marrow transplantation Bone Marrow Transplant 3 1988 625 630
54. A.M. Marmont, M.M. Horowitz, R.P. Gale, K. Sobocinski, R.C. Ash, D.W. van Bekkum T-cell depletion of HLA-identical transplants in leukemia Blood 78 1991 2120 2130
55. R. Champlin, S. Giralt, J. Gajewski T cells, graft-versus-host disease and graft-versus-leukemia Innovative approaches for blood and marrow transplantation Acta Haematol 95 1996 157 163
56. S. Auffermann-Gretzinger, I.S. Lossos, T.A. Vayntrub, W. Leong, F.C. Grumet, K.G. Blume Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients Blood 99 2002 1442 1448
57. W.D. Shlomchik, M.S. Couzens, C.B. Tang, J. McNiff, M.E. Robert, J. Liu Prevention of graft versus host disease by inactivation of host antigen-presenting cells Science 285 1999 412 415
58. Y.J. Liu, H. Kanzler, V. Soumelis, M. Gilliet Dendritic cell lineage, plasticity and cross-regulation Nat Immunol 2 2001 585 589
59. M. Arpinati, C.L. Green, S. Heimfeld, J.E. Heuser, C. Anasetti Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells Blood 95 2000 2484 2490
60. E.K. Waller, H. Rosenthal, L. Sagar DC2 effect on survival following allogeneic bone marrow transplantation Oncology (Williston Park) 16 2002 19 26
61. E.K. Waller, H. Rosenthal, T.W. Jones, J. Peel, S. Lonial, A. Langston Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation Blood 97 2001 2948 2956
62. T. Alcindor, G. Gorgun, K.B. Miller, T.F. Roberts, K. Sprague, D.P. Schenkein Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease Blood 98 2001 1622 1625